Valeritas Inc. announced last week that Endocrine Practice published a reflective study analysis titled “Clinical and Cost Effectiveness of Insulin Delivery with V-Go Disposable Insulin Delivery Device versus Multiple Daily Injections in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin."
Endocrine Practice is the certified peer-reviewed journal of the American Association of Clinical Endocrinologists (AACE).
When patients do not reach glycemic goals while undergoing basal insulin programs, the next step in the insulin therapy is to add in mealtime insulin to strengthen the treatment. V-Go, a disposable insulin delivery system designed to dispense basal-bolus insulin therapy for adults with Type 2 diabetes, has been proven by previous studies to be an effective means of delivering basal-bolus insulin.
V-Go has yet to be compared to other types of traditional insulin delivery methods in both cost and effectiveness. The goal of the study published in Endocrine Practice is to compare V-Go with subcutaneous multiple daily injections (MDI).
It was proven that the daily doses of patients transferred to the V-Go style of therapy remained very similar to the baseline set for the study. Those patients who were converted to MDI had their daily doses increase significantly.